Sequent Scientific has approved the issue and allotment of 3,000 Equity Shares of Rs. 2/- each fully paid to one Employee at an exercise price of Rs. 86/- per equity share on exercise of the options granted to him under SeQuent ESOP 2020.
The Board of Sequent Scientific at the meeting held on 20 May 2025, has decided not declare the dividend for the financial year 2024-25. on the equity shares of the Company.
Sequent Scientific reports consolidated net profit of Rs 9.32 crore in the March 2025 quarter
20 - May - 2025 12:00 | 30 days ago
Net profit of Sequent Scientific reported to Rs 9.32 crore in the quarter ended March 2025 as against net loss of Rs 0.92 crore during the previous quarter ended March 2024. Sales rose 11.21% to Rs 401.70 crore in the quarter ended March 2025 as against Rs 361.20 crore during the previous quarter ended March 2024.
For the full year,net profit reported to Rs 21.88 crore in the year ended March 2025 as against net loss of Rs 35.88 crore during the previous year ended March 2024. Sales rose 13.26% to Rs 1551.37 crore in the year ended March 2025 as against Rs 1369.73 crore during the previous year ended March 2024.
The Board of Sequent Scientific at the meeting held on 20 May 2025, has decided not declare the dividend for the financial year 2024-25. on the equity shares of the Company.
Sequent Scientific reports consolidated net profit of Rs 9.32 crore in the March 2025 quarter
20 - May - 2025 12:00 | 30 days ago
Net profit of Sequent Scientific reported to Rs 9.32 crore in the quarter ended March 2025 as against net loss of Rs 0.92 crore during the previous quarter ended March 2024. Sales rose 11.21% to Rs 401.70 crore in the quarter ended March 2025 as against Rs 361.20 crore during the previous quarter ended March 2024.
For the full year,net profit reported to Rs 21.88 crore in the year ended March 2025 as against net loss of Rs 35.88 crore during the previous year ended March 2024. Sales rose 13.26% to Rs 1551.37 crore in the year ended March 2025 as against Rs 1369.73 crore during the previous year ended March 2024.
Sequent Scientific has approved the issue and allotment of 3,000 Equity Shares of Rs. 2/- each fully paid to one Employee at an exercise price of Rs. 86/- per equity share on exercise of the options granted to him under SeQuent ESOP 2020.
The Board of Sequent Scientific at the meeting held on 20 May 2025, has decided not declare the dividend for the financial year 2024-25. on the equity shares of the Company.
Sequent Scientific reports consolidated net profit of Rs 9.32 crore in the March 2025 quarter
20 - May - 2025 12:00 | 30 days ago
Net profit of Sequent Scientific reported to Rs 9.32 crore in the quarter ended March 2025 as against net loss of Rs 0.92 crore during the previous quarter ended March 2024. Sales rose 11.21% to Rs 401.70 crore in the quarter ended March 2025 as against Rs 361.20 crore during the previous quarter ended March 2024.
For the full year,net profit reported to Rs 21.88 crore in the year ended March 2025 as against net loss of Rs 35.88 crore during the previous year ended March 2024. Sales rose 13.26% to Rs 1551.37 crore in the year ended March 2025 as against Rs 1369.73 crore during the previous year ended March 2024.
Sequent Scientific has approved the issue and allotment of 3,000 Equity Shares of Rs. 2/- each fully paid to one Employee at an exercise price of Rs. 86/- per equity share on exercise of the options granted to him under SeQuent ESOP 2020.
The Board of Sequent Scientific at the meeting held on 20 May 2025, has decided not declare the dividend for the financial year 2024-25. on the equity shares of the Company.
Sequent Scientific reports consolidated net profit of Rs 9.32 crore in the March 2025 quarter
20 - May - 2025 12:00 | 30 days ago
Net profit of Sequent Scientific reported to Rs 9.32 crore in the quarter ended March 2025 as against net loss of Rs 0.92 crore during the previous quarter ended March 2024. Sales rose 11.21% to Rs 401.70 crore in the quarter ended March 2025 as against Rs 361.20 crore during the previous quarter ended March 2024.
For the full year,net profit reported to Rs 21.88 crore in the year ended March 2025 as against net loss of Rs 35.88 crore during the previous year ended March 2024. Sales rose 13.26% to Rs 1551.37 crore in the year ended March 2025 as against Rs 1369.73 crore during the previous year ended March 2024.
The Board of Sequent Scientific at the meeting held on 20 May 2025, has decided not declare the dividend for the financial year 2024-25. on the equity shares of the Company.
Sequent Scientific reports consolidated net profit of Rs 9.32 crore in the March 2025 quarter
20 - May - 2025 12:00 | 30 days ago
Net profit of Sequent Scientific reported to Rs 9.32 crore in the quarter ended March 2025 as against net loss of Rs 0.92 crore during the previous quarter ended March 2024. Sales rose 11.21% to Rs 401.70 crore in the quarter ended March 2025 as against Rs 361.20 crore during the previous quarter ended March 2024.
For the full year,net profit reported to Rs 21.88 crore in the year ended March 2025 as against net loss of Rs 35.88 crore during the previous year ended March 2024. Sales rose 13.26% to Rs 1551.37 crore in the year ended March 2025 as against Rs 1369.73 crore during the previous year ended March 2024.
